Small Uncontrolled Trial Links Oxaloacetate to Improved Cognition After Breast Cancer
A small, uncontrolled phase II trial associated eight weeks of oxaloacetate with improved cognition, fatigue and physical functioning in 16 ...
Tag: Phase II trial
Research report: PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
A small, single-arm phase II study found a 56.3% response rate with first-line cadonilimab plus PF chemotherapy in 16 patients ...
Single-arm trial reports orelabrutinib response in high-risk lymphoma
In a prospective, multicenter, single-arm phase II trial conducted at four centers in China, orelabrutinib plus R-CDOP was associated with ...
Single-arm phase II trial reports strong response with junctional cancer combination
A single-arm phase II trial of 40 patients with locally advanced esophagogastric junction adenocarcinoma reported high pathological response rates, manageable ...
Antifibrotic Drug Pirfenidone Cuts Lung Injury Risk in Immunotherapy-Treated Lung Cancer Patients
A phase II trial found that prophylactic pirfenidone significantly reduced grade 2 or higher radiation-induced lung injury in lung cancer ...
Pill-Based HER2 Blocker Matches Standard Antibody Duo in Early Breast Cancer Trial
A multicenter phase II trial found that a pyrotinib-based neoadjuvant regimen achieved pathological response rates comparable to the standard trastuzumab-pertuzumab ...
Chemoimmunotherapy Before Surgery Lets Some Head and Neck Cancer Patients Skip High-Dose Radiation
A phase II trial found that preoperative chemo-immunotherapy with sintilimab achieved major pathological responses in 59.1 percent of locally advanced ...
New Trial Tests Oral Drug Plus Nanoliposomal Irinotecan for Hard-to-Treat Bile Duct Cancer
A German phase II trial called TRITICC-2 is testing whether oral trifluridine/tipiracil combined with nanoliposomal irinotecan can improve outcomes for ...
Nerve Growth Factor Eye Drops Show Four-Year Safety in Children With Optic Pathway Gliomas
A four-year observational follow-up of children treated with nerve growth factor eye drops in a randomized phase II trial shows ...
Immunotherapy After Surgery Shows Durable Results in High-Risk Esophageal Cancer
A phase II trial found that adjuvant sintilimab monotherapy after surgery met its primary efficacy endpoint with 87.5 percent one-year ...
-
Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study
-
University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept
-
Bee body mass, pathogens and local climate influence heat tolerance
-
Researchers record first-ever images and data of a shark experiencing a boat strike
-
Groundbreaking Clinical Trial Reveals Lubiprostone Enhances Kidney Function
Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!